Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro

Rodney Pommier, E. A. Woltering, G. Milo, W. S. Fletcher

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Dimethyl sulfoxide is a well-known differentiating agent that has been shown to inhibit tumor growth in vitro. We hypothesized that antineoplastic agents might show synergistic cytotoxicity when combined with 10% dimethyl sulfoxide. Twenty-four malignant ovarian tumors were removed and used in tests to determine the cytotoxicities of 10% dimethyl sulfoxide alone, each of six antineoplastic agents alone, and 10% dimethyl sulfoxide plus each antineoplastic agent. Cytotoxicity results for 10% dimethyl sulfoxide alone and each antineoplastic agent alone were used to evaluate each combination of dimethyl sulfoxide and an antineoplastic agent for synergy. There were 14 synergistic responses that were statistically significant at the p <0.01 confidence level between 10% dimethyl sulfoxide and an antineoplastic agent against the ovarian tumors. Seven of these responses were significant at the p <0.0003 level. This is strong evidence that true synergistic cytotoxicity occurs when an antineoplastic agent is combined with 10% dimethyl sulfoxide. We conclude that intraperitoneal delivery of antineoplastic agents in 10% dimethyl sulfoxide may be useful in the treatment of certain ovarian cancers.

    Original languageEnglish (US)
    Pages (from-to)848-852
    Number of pages5
    JournalAmerican Journal of Obstetrics and Gynecology
    Volume159
    Issue number4
    StatePublished - 1988

    Fingerprint

    Dimethyl Sulfoxide
    Antineoplastic Agents
    Ovarian Neoplasms
    Antineoplastic Combined Chemotherapy Protocols
    In Vitro Techniques
    Neoplasms
    Growth

    ASJC Scopus subject areas

    • Medicine(all)
    • Obstetrics and Gynecology

    Cite this

    Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro. / Pommier, Rodney; Woltering, E. A.; Milo, G.; Fletcher, W. S.

    In: American Journal of Obstetrics and Gynecology, Vol. 159, No. 4, 1988, p. 848-852.

    Research output: Contribution to journalArticle

    @article{0dd6a9666ece4d60b0b0820eb4f2352e,
    title = "Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro",
    abstract = "Dimethyl sulfoxide is a well-known differentiating agent that has been shown to inhibit tumor growth in vitro. We hypothesized that antineoplastic agents might show synergistic cytotoxicity when combined with 10{\%} dimethyl sulfoxide. Twenty-four malignant ovarian tumors were removed and used in tests to determine the cytotoxicities of 10{\%} dimethyl sulfoxide alone, each of six antineoplastic agents alone, and 10{\%} dimethyl sulfoxide plus each antineoplastic agent. Cytotoxicity results for 10{\%} dimethyl sulfoxide alone and each antineoplastic agent alone were used to evaluate each combination of dimethyl sulfoxide and an antineoplastic agent for synergy. There were 14 synergistic responses that were statistically significant at the p <0.01 confidence level between 10{\%} dimethyl sulfoxide and an antineoplastic agent against the ovarian tumors. Seven of these responses were significant at the p <0.0003 level. This is strong evidence that true synergistic cytotoxicity occurs when an antineoplastic agent is combined with 10{\%} dimethyl sulfoxide. We conclude that intraperitoneal delivery of antineoplastic agents in 10{\%} dimethyl sulfoxide may be useful in the treatment of certain ovarian cancers.",
    author = "Rodney Pommier and Woltering, {E. A.} and G. Milo and Fletcher, {W. S.}",
    year = "1988",
    language = "English (US)",
    volume = "159",
    pages = "848--852",
    journal = "American Journal of Obstetrics and Gynecology",
    issn = "0002-9378",
    publisher = "Mosby Inc.",
    number = "4",

    }

    TY - JOUR

    T1 - Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro

    AU - Pommier, Rodney

    AU - Woltering, E. A.

    AU - Milo, G.

    AU - Fletcher, W. S.

    PY - 1988

    Y1 - 1988

    N2 - Dimethyl sulfoxide is a well-known differentiating agent that has been shown to inhibit tumor growth in vitro. We hypothesized that antineoplastic agents might show synergistic cytotoxicity when combined with 10% dimethyl sulfoxide. Twenty-four malignant ovarian tumors were removed and used in tests to determine the cytotoxicities of 10% dimethyl sulfoxide alone, each of six antineoplastic agents alone, and 10% dimethyl sulfoxide plus each antineoplastic agent. Cytotoxicity results for 10% dimethyl sulfoxide alone and each antineoplastic agent alone were used to evaluate each combination of dimethyl sulfoxide and an antineoplastic agent for synergy. There were 14 synergistic responses that were statistically significant at the p <0.01 confidence level between 10% dimethyl sulfoxide and an antineoplastic agent against the ovarian tumors. Seven of these responses were significant at the p <0.0003 level. This is strong evidence that true synergistic cytotoxicity occurs when an antineoplastic agent is combined with 10% dimethyl sulfoxide. We conclude that intraperitoneal delivery of antineoplastic agents in 10% dimethyl sulfoxide may be useful in the treatment of certain ovarian cancers.

    AB - Dimethyl sulfoxide is a well-known differentiating agent that has been shown to inhibit tumor growth in vitro. We hypothesized that antineoplastic agents might show synergistic cytotoxicity when combined with 10% dimethyl sulfoxide. Twenty-four malignant ovarian tumors were removed and used in tests to determine the cytotoxicities of 10% dimethyl sulfoxide alone, each of six antineoplastic agents alone, and 10% dimethyl sulfoxide plus each antineoplastic agent. Cytotoxicity results for 10% dimethyl sulfoxide alone and each antineoplastic agent alone were used to evaluate each combination of dimethyl sulfoxide and an antineoplastic agent for synergy. There were 14 synergistic responses that were statistically significant at the p <0.01 confidence level between 10% dimethyl sulfoxide and an antineoplastic agent against the ovarian tumors. Seven of these responses were significant at the p <0.0003 level. This is strong evidence that true synergistic cytotoxicity occurs when an antineoplastic agent is combined with 10% dimethyl sulfoxide. We conclude that intraperitoneal delivery of antineoplastic agents in 10% dimethyl sulfoxide may be useful in the treatment of certain ovarian cancers.

    UR - http://www.scopus.com/inward/record.url?scp=0023808262&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0023808262&partnerID=8YFLogxK

    M3 - Article

    VL - 159

    SP - 848

    EP - 852

    JO - American Journal of Obstetrics and Gynecology

    JF - American Journal of Obstetrics and Gynecology

    SN - 0002-9378

    IS - 4

    ER -